SCHEMBL30179280

SCHEMBL30179280

O=C(ON1C(=O)CCC1=O)c1ccc(-c2c3ccc(=O)cc-3oc3cc(O)ccc23)c(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MEN1 O00255 2/20 0.53
POLB P06746 2/20 0.53
KMT2A Q03164 2/20 0.53
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
CA9 Q16790 14/20 0.53
ATM Q13315 1/20 0.51
PLEC Q15149 1/20 0.51
CA1 P00915 12/20 0.50
CA2 P00918 12/20 0.50
CA12 O43570 6/20 0.50
ESR1 P03372 1/20 0.48
DNASE1L3 Q13609 1/20 0.48
PRMT1 Q99873 1/20 0.48
CA14 Q9ULX7 2/20 0.46
ALB P02768 1/20 0.45
CA7 P43166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL799734 1.00 USP2 (0.62) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL29399313 0.97 USP2 (0.58) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL29415506 0.94 USP2 (0.56) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL2054802 0.94 USP2 (0.56) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL3728723 0.93 USP2 (0.57) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL12238065 0.89 USP2 (0.47) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL31327372 0.88 USP2 (0.50) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL20912026 0.86 USP2 (0.57) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL29352834 0.86 USP2 (0.56) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL6693395 0.86 USP2 (0.56) USP2L3MBTL1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4378534-A2 CYCLOTIDES AS IMMUNOSUPPRESSIVE AGENTS Medizinische Universität Wien (AT) 2024-06-05 EP disclosed
EP-3431095-B1 CYCLOTIDES AS IMMUNOSUPPRESSIVE AGENTS UNIV WIEN MED (AT) 2023-11-01 EP disclosed
US-11730826-B2 Amphiphilic nanoparticles for delivery of CRISPR based therapy MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-22 US disclosed
CN-113616807-B Mitochondrion-targeted polypeptide and preparation method and application thereof 中山大学 2023-07-21 CN disclosed
US-20230041271-A1 Mitochondria-Targeted Polypeptide, Preparation Method thereof, and Use thereof SUN YAT-SEN UNIVERSITY (CN) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730826-B2 Amphiphilic nanoparticles for delivery of CRISPR based therapy ABCB4, ABCB1, ZFR USP2 1247/4885L3MBTL1 354/4885MEN1 2357/4885
US-20230041271-A1 Mitochondria-Targeted Polypeptide, Preparation Method thereof, and Use thereof MTPN, TIMM13, TIMM10 USP2 3871/4885L3MBTL1 1637/4885MEN1 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.